Daniel E. Rees

daniel.rees@lw.com

+1.714.755.2244

Profile

Daniel Rees is a partner and a member of the firm's Corporate Department and Diversity Leadership Committee.

Mr. Rees advises clients on mergers and acquisitions and other strategic corporate transactions. He regularly provides general representation to public and private company clients, including on corporate and securities law matters, takeover defense, and securities offerings.

Mr. Rees represents companies in the healthcare and life sciences, technology, and real estate industries.

Experience

Mr. Rees’ representative transactions include advising:

Mergers & Acquisitions

Funds managed by PIMCO in the US$3.9 billion acquisition of Columbia Property Trust
Amgen in its acquisition of Teneobio for up to US$2.5 billion in upfront cash and contingent regulatory milestones
Switch in its US$420 million acquisition of Data Foundry
CoStar in its acquisitions of Homesnap and Homes.com
Cryoport in its US$320 million acquisition of MVE Biological Solutions from Chart Industries and its US$275 million private placement of preferred and common equity with Blackstone
Amgen in its investment in a 20.5% stake in BeiGene for US$2.7 billion
Impact Biomedicines in its sale to Celgene for up to US$7 billion in upfront cash and contingent regulatory approval and sales-based milestones
ICU Medical in its US$900 million acquisition of the Hospira Infusion Systems business of Pfizer
Air Medical Resource Group in its sale to Air Medical Group Holdings
Allergan in its:
- US$40.5 billion Global Generic Pharmaceuticals Business sale to Teva
- US$73 billion sale to Actavis
- US$54 billion hostile takeover attempt by Valeant Pharmaceuticals International (and associated proxy contest lead by Pershing Square and Bill Ackman)
PIMCO in its acquisition of Gurtin Municipal Bond Management
ST Telemedia in CenturyLink’s US$34 billion acquisition of Level 3 Communications, Inc.
J.P. Morgan as financial advisor to Intralinks Holdings in its US$821 million sale to Synchronoss Technologies
Waypoint in its sale of its management platform to Starwood
Ra Pharmaceuticals in its US$2.1 billion sale to UCB
Akebia Therapeutics in its merger of equals with Keryx Biopharmaceuticals
Aratana Therapeutics in its US$234 million sale to Elanco Animal Health
Medicis Pharmaceutical in its US$2.6 billion sale to Valeant Pharmaceuticals
Complete Production Services in its US$6.2 billion combination with Superior Energy Services
Golden State Foods in the sale of its McDonald’s food distribution business to Martin Brower
Starbucks in the US$384 million sale of its Tazo tea business
Incipio in its acquisition of Incase
NextGen in its acquisition of Mirth Corporation
5.11 Tactical in its acquisition of Beyond Clothing
Paul Frank in its sale to Saban Brands
T. Christy Enterprises in its sale to IPS Corporation
California Creative Brands in its sale to Sabra

Capital Markets

Cryoport in its follow-on offering of common stock
ICU Medical in secondary offerings of common stock
PDL BioPharma in its equity investment in, and dividend distribution of, Evofem Biosciences
Landmark Infrastructure Partners LP in its IPO of common stock and other securities offerings
Aratana Therapeutics in its IPO of common stock
Skullcandy in its IPO of common stock
Raptor Pharmaceutical and CoreCivic in “at-the-market” offerings of common stock
CoreCivic in offerings of registered debt securities
Realty Income Corporation in equity offerings of common stock
CoreLogic in 144A offerings of senior notes
Bank of America Merrill Lynch, Citigroup, Goldman Sachs, Jefferies, J.P. Morgan, Leerink and Piper Jaffray in follow-on offerings or IPOs, by Corium, Inogen, Glaukos, Green Plains Renewable Energy, MAKO Surgical, Sientra and YM BioSciences